Yu Y - Search Results

1

Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.

Pan T, Dan Y, Guo D, Jiang J, Ran D, Zhang L, Tian B, Yuan J, Yu Y, Gan Z. Pan T, et al. Among authors: yu y. Eur J Med Chem. 2021 Nov 15;224:113672. doi: 10.1016/j.ejmech.2021.113672. Epub 2021 Jun 29. Eur J Med Chem. 2021. PMID: 34237620

2

Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.

Yu Y, Ran D, Jiang J, Pan T, Dan Y, Tang Q, Li W, Zhang L, Gan L, Gan Z. Yu Y, et al. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2136-2140. doi: 10.1016/j.bmcl.2019.06.059. Epub 2019 Jun 29. Bioorg Med Chem Lett. 2019. PMID: 31272794

3

Tetrazanbigen Derivatives as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Partial Agonists: Design, Synthesis, Structure-Activity Relationship, and Anticancer Activities.

Gan L, Gan Z, Dan Y, Li Y, Zhang P, Chen S, Ye Z, Pan T, Wan C, Hu X, Yu Y. Gan L, et al. Among authors: yu y. J Med Chem. 2021 Jan 28;64(2):1018-1036. doi: 10.1021/acs.jmedchem.0c01512. Epub 2021 Jan 10. J Med Chem. 2021. PMID: 33423463

4

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer.

Guo D, Yu Y, Long B, Deng P, Ran D, Han L, Zheng J, Gan Z. Guo D, et al. Among authors: yu y. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2512-2529. doi: 10.1080/14756366.2022.2121822. J Enzyme Inhib Med Chem. 2022. PMID: 36100230 Free PMC article.

5

T-17, a novel cyclin-dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis.

Zhang L, Long R, Li X, Jiang J, Chen H, Tian B, Long B, Yu Y, Gan Z. Zhang L, et al. Among authors: yu y. Drug Dev Res. 2022 Nov;83(7):1578-1588. doi: 10.1002/ddr.21977. Epub 2022 Jul 17. Drug Dev Res. 2022. PMID: 35844039

6

The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats.

Li R, Zhou S, Gan Z, Wang L, Yu Y. Li R, et al. Among authors: yu y. Molecules. 2022 Apr 18;27(8):2594. doi: 10.3390/molecules27082594. Molecules. 2022. PMID: 35458793 Free PMC article.

7

TNBG-5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor γ in vitro and in vivo.

Hu X, Wan C, Gan Z, Liu R, Chen Y, Wang J, Gan L, Chen Y, Li Y, He B, Yu Y. Hu X, et al. Among authors: yu y. J Pharm Pharmacol. 2019 Nov;71(11):1684-1694. doi: 10.1111/jphp.13159. Epub 2019 Aug 25. J Pharm Pharmacol. 2019. PMID: 31446646

8

PTEN inhibition leads to the development of resistance to novel isoquinoline derivative TNBG-5602 in human liver cancer cells.

Wang J, Li Y, Wan CM, Gan ZJ, Gan LL, He BC, Yu Y, Hu XL. Wang J, et al. Among authors: yu y. Am J Cancer Res. 2021 Sep 15;11(9):4515-4527. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659902 Free PMC article.

9

Studies on the stereoselective synthesis and immunosuppressive activity of dihydroartemisinin-O-glycoside derivatives.

Yu Y, Yu J, Zou X, Xu W, Zhang J, Bian H, Dong X, Shen Z. Yu Y, et al. Among authors: yu j. Bioorg Med Chem Lett. 2020 Aug 15;30(16):127338. doi: 10.1016/j.bmcl.2020.127338. Epub 2020 Jun 10. Bioorg Med Chem Lett. 2020. PMID: 32631539

10

[Effects of TNBG on the proliferation and apoptosis of human hepatocellular carcinoma cell line QGY-7701].

Li LJ, Yu Y, Tang WX, Chen ZQ, Yuan YH, Yang XL. Li LJ, et al. Among authors: yu y. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):372-4. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005. PMID: 15931872 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,282 results

Search Page

Filters